(Q46782213)

25 December 2017

title

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. (English)

1 reference

25 December 2017

1 reference

11

Daniel A Haber

1 reference

25 December 2017

author name string

Daphne W Bell

1

1 reference

25 December 2017

Ira Gore

2

1 reference

25 December 2017

Ross A Okimoto

3

1 reference

25 December 2017

Nadia Godin-Heymann

4

1 reference

25 December 2017

Raffaella Sordella

5

1 reference

25 December 2017

Roseann Mulloy

6

1 reference

25 December 2017

Sreenath V Sharma

7

1 reference

25 December 2017

Brian W Brannigan

8

1 reference

25 December 2017

Gayatry Mohapatra

9

1 reference

25 December 2017

Jeff Settleman

10

1 reference

25 December 2017

language of work or name

English

0 references

publication date

30 October 2005

1 reference

25 December 2017

published in

Nature Genetics

1 reference

25 December 2017

volume

37

1 reference

25 December 2017

issue

12

1 reference

25 December 2017

page(s)

1315-1316

1 reference

25 December 2017

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

cites work

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

21 January 2018

1 reference

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

21 January 2018

1 reference

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

21 January 2018

1 reference

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1038/NG1671

1 reference

25 December 2017

1 reference

25 December 2017